Western Canada Chronic Disease Management Infostructure Initiative
|
|
- Jade Malone
- 6 years ago
- Views:
Transcription
1 Western Health Information Collaborative (WHIC) Western Canada Chronic Disease Management Infostructure Initiative - 07/06/2005 2:39 PM Prepared by Western Health Information Collaborative Data Standards and HL7 Messaging Project Team June 29, 2005 Version 7.1
2 Page i Disclaimer: The contents of this document are in a DRAFT state. As such, the reader should be aware that the contents are still undergoing revision. The WHIC Chronic Disease Management (CDM) project is sharing this document for information purposes, and we would request that the document not be distributed further at this time. Once the final version of the document is completed and approved by the WHIC CDM Steering Committee, it will be posted to the CDM page at the WHIC public web site at
3 Page ii TABLE OF CONTENTS 1. Introduction Clinical Data Attributes Type Procedure type Medication / Vaccine type Observation type Diagnostic image type Planned procedure type Planned observation type Planned diagnostic image type Goal type Identifier Procedure identifier Medication / Vaccine prescription or dispense identifier Observation identifier Diagnostic image identifier Referral identifier Observation Value Observation Interpretation Method Code Observation method code Diagnostic image method code Date (Measured, Performed) Procedure date Observation date Diagnostic image date Date (Entered, Recorded) Y/N Indicator Procedure occurred indicator Medication / Vaccine occurred indicator Observation occurred indicator Diagnostic image occurred indicator... 10
4 Page iii 2.9. Non Performance Reason Code Procedure non performance reason Medication / Vaccine not given reason Observation non performance reason Diagnostic image non performance reason Referral reason code Referral encounter occurred indicator Referral encounter date Referral encounter non performance reason Observation Normal Range Details Procedure details Medication / Vaccine details Observation details Diagnostic image details Referral details Medication / Vaccine name Medication / Vaccine dose Medication / Vaccine frequency Medication / Vaccine route Medication / Vaccine flag Goal value Goal value target date Reassessment date Medication / Vaccine dispense date Date Ordered Planned observation diagnosis value... 16
5 Page 1 1. INTRODUCTION The primary purpose of the Western Canada Chronic Disease Management (CDM) Infostructure Initiative is to develop chronic disease management data standards and information interchange messages, and to support the implementation of this infostructure within the four participating western provinces (British Columbia, Alberta, Saskatchewan, and Manitoba). The CDM Data Standards have been prepared to describe in clinical terms the scope, content and details of the CDM Data Standards developed for the Western Canada CDM Infostructure Initiative. This document is intended primarily for a clinical / business audience 1. The CDM Data Standards have been organized as follows: CDM Data Standards Introduction This document provides background information on the Western Canada CDM Infostructure Initiative, provides an overview of the Phase 2 Data Standards and HL7 Messaging project, describes the Chronic Disease Model, and provides an overview of the record and clinical data elements. Appendix A Coding Systems Includes an overview of the coding systems considered for the CDM Data Standards, describes the criteria and process for selection, and identifies special considerations and explanations for the selected code systems. Appendix B Record Level Data The record level data or structural data elements are generic data elements that are fixed and are provided regardless of the type of chronic disease. This appendix provides the data definition, and identifies the data type and valid values for each of the data elements. Appendix C Clinical Data Clinical data elements are specific data elements that pertain to chronic diseases. These data elements provide clinical information to assist clinicians in managing individuals with 1 For more technical documentation on the CDM HL7 Message Specifications, please refer to the CDM HL7 Message Specifications Implementation Guide.
6 Page 2 chronic diseases. This appendix provides the data definition, and identifies the data type (type code, type code value, type code name) and code table for each of the data elements. Appendix D Detail Data The detailed data attributes give additional specifics on the clinical data elements. The attributes describe the characteristics or details to be captured on person history, physical exams, lab tests, medications, procedures, etc. This appendix provides the data definition, and identifies the data type and valid values for each of the data elements. Appendix E Code Tables This appendix provides the details for the defined code sets that will be used for the CDM data elements (e.g. Code table name, source, codes, descriptions, print names, etc.).
7 Page 3 2. CLINICAL DATA ATTRIBUTES 2.1. Type Includes TYPE The form of procedure, observation, diagnostic image, etc. Procedure type Medication / Vaccine type Observation type Diagnostic image type Planned procedure type Planned observation type Planned diagnostic image type Goal type Procedure type Procedure type Indicates the type of procedure(s) performed. See Appendix E for Procedure Type Medication / Vaccine type Medication / Vaccine type A code uniquely identifying the medication or vaccine. See Appendix E for Medication / Vaccine Type
8 Page Observation type Observation type Indicates what sort of test or observation was actually performed. See Appendix E for Observation Type Diagnostic image type Diagnostic image type Identifies the type of image that was taken. See Appendix E for Diagnostic Image Type Planned procedure type Planned procedure type Indicates the type of procedure to be performed (e.g. kind of education, type of surgery etc.). See Appendix E for Procedure Type Planned observation type Planned observation type A code specifying the type of clinical observation planned to be made at some time in the future (e.g. height, weight, a particular lab test etc.). See Appendix E for Observation Type Planned diagnostic image type Planned diagnostic image type Indicates what type of image is to be taken. See Appendix E for Diagnostic Image Type
9 Page Goal type Goal type The type of measurement for which the target is being set e.g. BMI. See Appendix E for Goal Type 2.2. Identifier Includes IDENTIFIER A unique identifier (numeric, alpha or alpha-numeric) used for reference purposes Procedure identifier Medication / Vaccine prescription or dispense identifier Observation identifier Diagnostic image identifier Referral identifier Procedure identifier Procedure identifier A unique identifier assigned to a particular occurrence of a procedure. II Instance Identifier Medication / Vaccine prescription or dispense identifier Medication / Vaccine prescription or dispense identifier A unique identifier assigned to the prescription or dispensing record. II Instance Identifier Observation identifier Observation identifier A unique identifier for the observation. II Instance Identifier
10 Page Diagnostic image identifier Diagnostic image identifier A unique identifier for the diagnostic image II Instance Identifier Referral identifier Referral identifier A unique identifier for the referral. II Instance Identifier 2.3. Observation Value OBSERVATION VALUE The observed value of the variable being tested. May be expressed as a numeric quantity, as a code, or as free text, or in some other ways depending on the particular test. ANY 2.4. Observation Interpretation OBSERVATION INTERPRETATION Many times in addition to (or possibly instead of) reporting a physical measurement, a laboratory will indicate that the reported value is high, low, normal, or some other coded interpretation. Even when there is a value, interpretation is often offered to help convey the significance of a particular result. See Appendix E for Observation Interpretation and Retinopathy Interpretation
11 Page Method Code Includes METHOD CODE A unique code number that describes a way of doing something or obtaining information. In the CDM project, method code may refer to whether information on the person or chronic condition was reported by the person or observed by the service provider; or whether the approach to taking a physical measurement such as blood pressure was done with the person sitting or lying down, etc. Observation method code Diagnostic image method code Observation method code Observation method code Indicates the means or technique used to perform the test or observation. See Appendix E for Observation Method Code Diagnostic image method code Diagnostic image method code Indicates the means or technique used to perform the imaging. See Appendix E for Diagnostic Image Method Code 2.6. Date (Measured, Performed) Includes DATE (MEASURED, PERFORMED) Date when a lab test, procedure, examination, etc. was measured or performed on the person. Procedure date Observation date Diagnostic image date
12 Page Procedure date Procedure date The calendar date on which the person received health services by a provider. TS.DATE Timestamp Limited to date only, may be YYYY, YYYYMM or YYYYMMDD Observation date Observation date The biologically relevant date at which the observation was measured / performed / collected. In the case of a lab test this refers to the date the specimen was collected. (e.g., the date the blood was collected / drawn for testing). In the case of an examination the date refers to when the exam was performed (e.g., systolic and diastolic blood pressure). In the case of a diagnosis the date refers to when the condition is believed to have been diagnosed (e.g., depression). TS.DATE Timestamp Diagnostic image date Limited to date only, may be YYYY, YYYYMM or YYYYMMDD Diagnostic image date The date the diagnostic image was actually performed. TS.FULLDATE Timestamp Limited to date only, must specify all of YYYYMMDD 2.7. Date (Entered, Recorded) DATE (ENTERED, RECORDED) The date the information was actually entered / recorded. TS.DATE Timestamp Limited to date only, may be YYYY, YYYYMM or YYYYMMDD
13 Page Y/N Indicator Includes Y/N INDICATOR A code that indicates whether information is available or not on the specific clinical area of interest, i.e., procedure, medication, lab test, etc. in the CDM record. Procedure occurred indicator Medication / Vaccine occurred indicator Observation occurred indicator Diagnostic image occurred indicator Procedure occurred indicator Procedure occurred indicator An indication whether the procedure occurred or not. Used as a simple Yes / No indicator. BL Boolean True or False Medication / Vaccine occurred indicator Medication / Vaccine occurred indicator An indication as to whether the medication is being taken or not, or whether the vaccine was administered or not. It is used as a simple Yes / No indicator. BL Boolean True or False Observation occurred indicator Observation occurred indicator An indication that a clinical observation was made or not (e.g., I have not observed an allergic reaction). BL Boolean True or False
14 Page Diagnostic image occurred indicator Diagnostic image occurred indicator An indication that the diagnostic image was done or not done e.g. a particular image of interest does not exist. BL Boolean True or False 2.9. Non Performance Reason Code Includes NON PERFORMANCE REASON CODE An explanation as to why an administrative correction, change in condition or referral occurred or why a procedure, observation, diagnostic image, etc. did not occur. Procedure non performance reason Medication / Vaccine not given reason Observation non performance reason Diagnostic image non performance reason Procedure non performance reason Procedure non performance reason The reason the procedure wasn't performed as expected. See Appendix E for Non Performance Reason Medication / Vaccine not given reason Medication / Vaccine not given reason The reason the Medication / Vaccine wasn't taken. See Appendix E for Non Performance Reason
15 Page Observation non performance reason Observation non performance reason The reason the action wasn't performed. See Appendix E for Non Performance Reason Diagnostic image non performance reason Diagnostic image non performance reason The reason the action wasn't performed. See Appendix E for Non Performance Reason Referral reason code REFERRAL REASON CODE The reason the referral was made according to the guidelines. See Appendix E for Reason Referral Code Referral encounter occurred indicator REFERRAL ENCOUNTER OCCURRED INDICATOR An indication whether the referral encounter occurred or did not occur. BL Boolean True or False Referral encounter date REFERRAL ENCOUNTER DATE Indicates the date of the first "point of contact" between the referred-to provider and the person with the chronic condition, as initiated by the referral. IVL.LOW<TS.FULLDATE> Lower-bounded date-range (includes start-date but duration and end-time are unspecified)
16 Page Referral encounter non performance reason REFERRAL ECNOUNTER NON PERFORMANCE REASON The reason the referral encounter did not occur. See Appendix E for Non Performance Reason Observation Normal Range OBSERVATION NORMAL RANGE Indicates the expected range for the observation in a healthy person. IVL<PQ> Details Includes DETAILS Additional information provided in a textual or narrative form regarding a lab test, procedure, medication, etc. Procedure details Medication / Vaccine details Observation details Diagnostic image details Referral details Procedure details Procedure details Provides additional detail about the procedure, such as how the procedure was performed (e.g., the modality), the body-site involved and other descriptive information. ST String
17 Page Medication / Vaccine details Medication / vaccine details Additional details about the medication therapy. ST String Observation details Observation details Additional details about the observation. ST String Diagnostic image details Diagnostic image details Additional details about the diagnostic image result that may affect its clinical interpretation for instance how the image was taken, what body part was imaged and the orientation the person assumed. ST String Referral details Referral details Additional details about the referral. ST String Medication / Vaccine name MEDICATION / VACCINE NAME A generic drug name is humanly readable for the medication, which is necessary in order to communicate effectively between service providers in respect of the person s medications. ST String
18 Page Medication / Vaccine dose MEDICATION / VACCINE DOSE The amount of medication prescribed by the service provider, for the person, intended to be consumed during a single administration. The quantity specified by the dose is intended to be taken once for each repetition indicated by the frequency. URG<PQ.MASSVOL> Medication / Vaccine frequency MEDICATION / VACCINE FREQUENCY Indicates the frequency with which a vaccine dose is administered (e.g., annually for influenza vaccine) and with which a medication is consumed (e.g., daily for aspirin). PIVL<TS> Repeating Interval Medication / Vaccine route MEDICATION / VACCINE ROUTE The route of administration of the medication. Common examples include "oral", "s.c.", (subcutaneous) or via continuous pump. See Appendix E Medication / Vaccine Route Medication / Vaccine flag MEDICATION / VACCINE FLAG An indicator of whether with the record represents a medication or a vaccine. See Appendix E for Medication / Vaccine Flag
19 Page Goal value GOAL VALUE The value of the measurement targeted to be achieved. May be expressed as a range (e.g., blood glucose between X and Y), or in comparison to a particular target number (e.g., BMI <25). ANY Goal value target date GOAL VALUE TARGET DATE The specific date the target should be achieved. IVL.HIGH<TS.FULLDATE> Interval Timestamp Limited to end date only, must specify all of YYYYMMDD Reassessment date REASSESSMENT DATE Indicates when a particular planned activity or type of activity is intended to be reviewed. For example, review medications on Mar. 1, TS.DATE Timestamp Limited to date only, may be YYYY, YYYYMM or YYYYMMDD Medication / Vaccine dispense date MEDICATION / VACCINE DISPENSE DATE The date the medication was dispensed to the person by a service provider, or the date the vaccine was actually injected into a person by the service provider delivering the vaccination services. TS.FULLDATE Timestamp Limited to date only, must specify all of YYYYMMDD
20 Page Date Ordered DATE ORDERED Indicates when the order for the specified event was created. TS.FULLDATE Timestamp Limited to date only, must specify all of YYYYMMDD Planned observation diagnosis value PLANNED OBSERVATION DIAGNOSIS VALUE This identifies the specific diagnosis to be reviewed. See Appendix E for Planned Observation Diagnosis Value
Western Canada Chronic Disease Management Infostructure Initiative
Western Health Information Collaborative (WHIC) Western Canada Chronic Disease Management Infostructure Initiative CDM Data Standards Introduction FINAL - 08/10/2005 12:19 PM Prepared by Western Health
More informationHow Logistics Enables the Healthcare Revolution. Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company
How Logistics Enables the Healthcare Revolution Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company Introduction There is a revolution taking place in healthcare delivery. Patient-centred
More informationPharmacy. Medication. Checks
Pharmacy Medication Checks Module 2 Table of Contents Section A... 1 A.1 Clinical Medication Order Check... 1 A.2 Final Product and Computer Order Entry Check... 1 Section B... 2 B.1 Documentation of Pharmacy
More informationNational Learning Consortium
National Learning Consortium The National Learning Consortium (NLC) is a virtual and evolving body of knowledge and tools designed to support healthcare providers and health IT professionals working towards
More informationMEANINGFUL USE CRITERIA PHYSICIANS
MEANINGFUL USE CRITERIA PHYSICIANS The first list is of the 25 Stage 1 Meaningful Use criteria for eligible providers (EP) and comes from the proposed rule: "Medicare and Medicaid Programs; Electronic
More informationChargemaster Fundamentals for a Solid Revenue Cycle Foundation. November 7, 2012 John Behn
Chargemaster Fundamentals for a Solid Revenue Cycle Foundation Understanding the Importance, Purpose and Function of your Charge Data Master November 7, 2012 John Behn National Rural Health Resource Center
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationQualifacts Carelogic Enterprise S2.15 Costs and Limitations of Certified Health IT
Carelogic Enterprise S2.15 Costs and Limitations Certified Health IT- January 2018 Update Qualifacts Carelogic Enterprise S2.15 Costs and Limitations of Certified Health IT Capability Description of Capability
More information2015 Small Group Incentive Wellness For Metallic Plans Employer Q&A
2015 Small Group Incentive Wellness For Metallic Plans Employer Q&A SGIWQA-WA 120114 General Program Information Q. What is the Small Group Incentive Wellness program? A. The Small Group Incentive Wellness
More informationPolicy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)
Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to
More informationFDA S DRAFT GUIDANCE ON MULTIPLE ENDPOINTS IN CLINICAL TRIALS: OVERVIEW, RECEPTION AND NEXT STEPS. John Scott, Ph.D. FDA/CBER 5 October 2017
FDA S DRAFT GUIDANCE ON MULTIPLE ENDPOINTS IN CLINICAL TRIALS: OVERVIEW, RECEPTION AND NEXT STEPS John Scott, Ph.D. FDA/CBER 5 October 2017 Disclaimer 2 This presentation reflects the views of the author
More informationNational standard adverse reaction dataset and clinical document architecture (CDA) template
National standard adverse reaction dataset and clinical document architecture (CDA) template January 2016 Safer Better Care Page 1 of 62 Page 2 of 62 About the The (HIQA) is an independent authority established
More informationFrequently Asked Questions Generics Tiered Pricing Framework
Frequently Asked Questions Generics Tiered Pricing Framework Tiered Pricing Framework (TPF) Generic Drug Category % of Brand Reference Pricing Notes Description/Tier 1 Tier 1: Single source (i.e. only
More informationIIS Competency Domain Model
IIS Competency Domain Model Knowledge, Skills and Abilities for IIS Job Roles PHII Academy 18 November 2015 www.informaticsacademy.org Standards and Interoperability Applies informatics standards to ensure
More informationASIAN PATENT ATTORNEYS ASSOCIATION Recognized Group of Korea. Report to Emerging IP Rights Committee 2012, Chiang Mai
ASIAN PATENT ATTORNEYS ASSOCIATION Recognized Group of Korea Report to Emerging IP Rights Committee 2012, Chiang Mai SPECIAL TOPIC REPORT ON Business Methods and the Laws of Nature, As Discussed by the
More informationCanadian Cancer Clinical Trials Network Portfolio Eligibility Criteria and Guidelines
Canadian Cancer Clinical Trials Network Portfolio Eligibility Criteria and Guidelines 1. Introduction The Canadian Cancer Clinical Trials Network (3CTN) will support a portfolio of academic clinical trials
More informationCOMMISSIONING IMMUNOGLOBULIN
COMMISSIONING IMMUNOGLOBULIN Advice to commissioners and commissioning bodies Dr. Henrietta E Ewart Consultant in Public Health Medicine, Solutions for Public Health Mr. Malcolm Qualie Head of Health Policy,
More informationMEANINGFUL USE AND PQRS
MEANINGFUL USE AND PQRS Understanding the Measures Presented By: Morgan Kuper, Customer Service Supervisor 2016 Meaningful Use Overview Objectives and Measures Exclusions Changes to Specific Objectives
More informationIHE IT Infrastructure (ITI) Technical Framework Supplement. Cross-Enterprise Document Workflow (XDW) Draft for Public Comment
Integrating the Healthcare Enterprise 5 IHE IT Infrastructure (ITI) Technical Framework Supplement 10 Cross-Enterprise Document Workflow (XDW) 15 Draft for Public Comment 20 Date: June 3, 2011 Author:
More informationTherapeutic monoclonal antibodies & blood transfusion Essential information for hospital transfusion laboratories, transfusion practitioners &
Therapeutic monoclonal antibodies & blood transfusion Essential information for hospital transfusion laboratories, transfusion practitioners & haematology clinical teams March 2018 Background Targeted
More informationCoordinated Primary Options Service. DVT Management Plan. Management options using Dabigatran or Warfarin
Coordinated Primary Options Service DVT Management Plan Management options using Dabigatran or Warfarin Name NHI DOB Ethnicity Gender Address Contact Information Mobile Home Treatment commenced date *CPO
More informationClinical Policy Guidelines. Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test.
NHS GREATER GLASGOW AND CLYDE BOWEL SCREENING PROGRAMME Clinical Policy Guidelines Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test. Date to
More informationFrequently Asked Questions about the Pan-Canadian Generic Value Price Initiative Generic Pricing Framework and Centralized Price Confirmation Process
Frequently Asked Questions about the Pan-Canadian Generic Value Price Initiative Generic Pricing Framework and Centralized Price Confirmation Process Category 2 Description New single source (i.e. only
More informationCRM and the Future of Healthcare Engagement
CRM and the Future of Healthcare Engagement CRM and the Future of Healthcare Engagement As a growing number of healthcare organizations are discovering, the most common technology in healthcare the electronic
More informationPROPRIETARY NAME REVIEW(S)
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125553Orig1s000 PROPRIETARY NAME REVIEW(S) PROPRIETARY NAME REVIEW Division of Medication Error Prevention and Analysis (DMEPA) Office of Medication
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationApplication form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE
Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE In completing this form please refer to the attached Notes of Guidance Application for approval of all studies involving Healthy
More informationClarifying digital health and software regulation: FDA releases three new guidance documents
Clarifying digital health and software regulation: FDA releases three new guidance documents December 15, 2017 On December 7, 2017, the Food and Drug Administration (FDA or the Agency) released three guidance
More informationDepartment of Family Relations and Applied Nutrition. NUTR*4040 Clinical Nutrition II Fall 2015 COURSE OUTLINE
Department of Family Relations and Applied Nutrition Instructor Dr. Laura Forbes Office: Macdonald Stewart Hall, Room 326 forbesl@uoguelph.ca Ext 52544 Office hours: TBA TA Kathryn Walton e-mail: kwalton@uoguelph.ca
More informationWolf EMR. New Product Features and Roadmap Update. Rowan Helmer, Sr. Product Manager. Western EMR User Conference 2016
Wolf EMR New Product Features and Roadmap Update Rowan Helmer, Sr. Product Manager Agenda 1. What have we done in 2016? 2. Coming Soon! 3. Roadmap Planning 4. Questions 2 What have we done in 2016? Driving
More informationPublished 13 June 2011 Page May 2011
filgrastim, 30 million units (300 micrograms)/0.5ml, 48 million units (480 micrograms)/0.5ml, solution for injection or infusion in pre-filled syringe (Zarzio ) SMC No. (704/11) Sandoz Ltd 06 May 2011
More informationGE Healthcare. EchoPAC Dimension 06. Clinical workstation
GE Healthcare EchoPAC Dimension 06 Clinical workstation Workflow that works for you. The freedom of choice extends to the echo lab with an information management solution that gives clinicians the ability
More informationZIMS - CORE BUSINESS FUNCTIONS
ZIMS - CORE BUSINESS FUNCTIONS Inventory Accession (JAD 1)/BUC300/PM043 Acquisition (JAD 1)/BUC301/PM044 Disposition (JAD 1)/BUC302/PM045 External Transfers (JAD 2)/BUC304/PM084 Inventory Reconciliation
More informationMHM - Healthy Michigan Plan
MHM - Healthy Michigan Plan What is Healthy Michigan Plan? The Healthy Michigan Plan is a new category of eligibility authorized under the Patient Protection and Affordable Care Act and Michigan Public
More informationMain Content Domain % of Operational Items # of Operational Items
The PCOA content areas and subtopics for the 2016-2017 administration are based upon the outcomes from the US College of Pharmacy Curricula Survey. The assessment is composed of four content areas that
More informationExpanded Access. to Investigational Drugs & Biologics. for Treatment Use
SJMHS Research Compliance Office Guidance Document Expanded Access to Investigational Drugs & Biologics for Treatment Use May 2015 1 Expanded Access to Investigational Drugs & Biologics for Treatment Use
More informationThe Drug Safety and Effectiveness Network (DSEN) Dr. Diane Forbes, Associate Director, DSEN CAPT 2012 Annual Conference, May 8, 2012
The Drug Safety and Effectiveness Network (DSEN) Dr. Diane Forbes, Associate Director, DSEN CAPT 2012 Annual Conference, May 8, 2012 The Drug Safety and Effectiveness Network - Background DSEN included
More informationARQ Sexually Transmitted Infections (STI) Intervention Sheet
ARQ Sexually Transmitted Infections (STI) Intervention Sheet Purpose The major purpose of PANCEA is to document intervention expenditures and associated outputs. We want to know how much it costs to provide
More informationStep-by-Step Description of ELISA
Step-by-Step Description of ELISA The protocols in this kit rely on indirect antibody capture ELISA. The steps in this assay are: Step 1: Antigen is added to the wells of the microplate strip and incubated
More informationPhysician Orders - Adult
Physician Orders - Adult attach patient label here Title: Direct Thrombin Inhibitor (DTI) Protocol Orders Height: cm Weight: kg Allergies: [ ] No known allergies [ ]Medication allergy(s): [ ] Latex allergy
More informationWELLNESS PROGRAM AND WEBSITE GUIDE
L i f e C h a n g e s D i s e a s e M a n a g e m e n t LIVE well M a n a g i n g S t r e s s G o o d N u t r i t i o n L i f e s t y l e F i t n e s s H e a l t h y H a b i t s WELLNESS PROGRAM AND WEBSITE
More informationDRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes
NHS ONEL & Barking, Havering & Redbridge University Hospitals Trust Shared Care Guidelines DRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #21 (NQF 0268): Perioperative Care: Selection of Prophylactic Antibiotic First OR Second Generation Cephalosporin National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL
More informationConnecticut Department of Social Services Medical Assistance Program Provider Bulletin. PB July 2008
Connecticut Department of Social Services Medical Assistance Program Provider Bulletin PB 2008-42 July 2008 TO: Hospital Providers SUBJECT: Most Frequently Asked Questions related to the billing requirements
More informationEliminating Infusion Confusion
Eliminating Infusion Confusion (Drug Administrations in Non-facility Settings) Maryann C. Palmeter, CPC, CENTC Agenda Review of CPT codes (added in 2009) Documentation principles Key definitions What s
More informationOREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE. OPERATING PROCEDURES Updated: March 2018
OREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE OPERATING PROCEDURES Updated: March 2018 MISSION: To encourage safe, effective, and innovative drug policies that promote high
More informationTEMPLATE LANGUAGE FOR MENTOR/MENTEE RELATIONSHIP AND COMPENSATION
TEMPLATE LANGUAGE FOR MENTOR/MENTEE RELATIONSHIP AND COMPENSATION Copyright Priority Press, Ltd. and James F. Wilson, DVM, JD Not For Use Without Author s Permission All language highlighted in bold, underlines
More informationIGRAs for Serial Testing of Healthcare Workers
IGRAs for Serial Testing of Healthcare Workers Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center Disclosures-Funding
More informationHL7 Plenary EHR In Canada
HL7 Plenary EHR In Canada September 11, 2006 Dennis Giokas Chief Technology Officer Canada Health Infoway, Inc Agenda Canada Health Infoway What is the EHR and It s Benefits Architecture and Standards
More informationMiramont Family Medicine
Miramont Family Medicine Adopted the Patient Centered Medical Home model to provide highest-quality, lowest-cost services to our patients Physician Owned Laboratory (POL) integral to delivery of our health
More informationGuidelines on Use of Haematopoietic Growth Factors in Adult Oncology and Haemato-oncology Patients
Guidelines on Use of Haematopoietic Growth Factors in Adult Oncology and Haemato-oncology Patients The recombinant human granulocyte-colony stimulating factor (GCSF) of choice is Biosimilar filgrastim
More informationREPORT. Text File Invoice PUBLIC. Report Format. Issue 5.0 IMP_REP_0049. This Technical Interface document describes the format of text file invoices.
REPORT PUBLIC IMP_REP_0049 Text File Invoice Report Format Issue 5.0 This Technical Interface document describes the format of text file invoices. Public Disclaimer The posting of documents on this Web
More informationHeal hybalance. A program to improve health and create a balanced lifestyle for your employees and your organization. Healthy starts here.
Heal hybalance A program to improve health and create a balanced lifestyle for your employees and your organization. Healthy starts here. The benefits of having healthier employees If you could, over time,
More informationA Physician s consideration towards Biosimilars. João Eurico Fonseca
A Physician s consideration towards Biosimilars João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis,
More informationEUROPEAN PATENT OFFICE U.S. PATENT AND TRADEMARK OFFICE CPC NOTICE OF CHANGES 473 DATE: JANUARY 1, 2018 PROJECT RP0486
EUROPEA PATET OFFICE U.S. PATET AD TRADEMARK OFFICE CPC OTICE OF CHAGES 473 The following classification changes will be effected by this otice of Changes: Action Subclass Group(s) SCHEME: Symbols Deleted:
More informationUniversity Of Pathology Informatics Certificate Of Completion Program
University Of Pathology Informatics Certificate Of Completion Program Course Program Syllabus Courses for Completion: 20 Type of Instruction: Online (and Blended where applicable) Administrative Notes
More informationCalendar Year 2018 Medicare Hospital Outpatient Prospective Payment System Proposed Rule
Calendar Year 2018 Medicare Hospital Outpatient Prospective Payment System Proposed Rule August 2017 This document is presented for informational purposes only and is not intended to provide reimbursement
More informationAccessing your HRA. If you are a new or existing UnitedHealthcare member. Tracking your Healthy Rewards on myuhc.com. Dear Member,
Dear Member, Now that you have enrolled in the Health Reimbursement Medical Plan option, we wanted to provide you with important information about your Health Reimbursement Account (HRA). Accessing your
More informationPayroll & Vacations: Is Your Organization Compliant?
One of the biggest anxieties for payroll professionals is dealing with annual vacations. While it may seem like a simple and straightforward aspect of the employment relationship, it is can be quite complex.
More informationHITT 1211 Final Exam Review (Chap 1-12)
HITT 1211 Final Exam Review (Chap 1-12) This exam is a two-part exam consisting of a comprehensive, closed-book exam over lecture text chapters 1 12 and a closed-book skills exam demonstrating your skills
More informationIntroduction to Pharmacogenetics Competency
Introduction to Pharmacogenetics Competency Updated on 6/2015 Pre-test Question # 1 Pharmacogenetics is the study of how genetic variations affect drug response a) True b) False Pre-test Question # 2 Pharmacogenetic
More informationQuality Rating System Scoring Specifications
Quality Rating System Scoring Specifications March 28, 2014 DRAFT CMS is accepting comments on the proposed QRS scoring specifications until April 28, 2014. Please email all comments to Marketplace_Quality@cms.hhs.gov
More informationCancer Vanguard. Biosimilars Trust Policy Template
Cancer Vanguard Biosimilars Trust Policy Template Aim of this document: The document provides generic guidance and outline for the development of local trust policies in relation to the adoption of biosimilars
More informationAssistant Practitioner Competency Framework
Assistant Practitioner Competency Framework January 2014 Review: January 2018 2010 Permission granted to reproduce for personal and educational use only. Commercial copying, hiring or lending without the
More informationPrescription Writing Version 4.81
Prescription Writing Version 4.81 Contents Introduction... 1 Field Definitions... 1 Patient Prescription Entry Window... 1 Void Patient Prescription Window... 5 Drug Dose Frequencies Window... 6 Pharmacies
More informationHealth Reimbursement Account Preventive Care Program for Participants and Spouses
Health Reimbursement Account Preventive Care Program for Participants and Spouses EFFECTIVE DATE: JANUARY 1, 2016 The Trustees have established the Health Reimbursement Account Preventive Care Program
More informationMeasure Harmonization. Guidance for Measure Harmonization A CONSENSUS REPORT
Measure Harmonization Guidance for Measure Harmonization A CONSENSUS REPORT National Quality Forum The National Quality Forum (NQF) operates under a three-part mission to improve the quality of American
More informationCentricity * Precision Reporting
GE Healthcare Centricity * Precision Reporting A more intelligent approach to diagnostic reporting. Healthcare IT Re-Imagined 1 1 1 0 0 1 0 1 0 0 0 0 *Trademark of General Electric Company. Imagine being
More informationAccessing Your HRA myuhc.com If You Are a New UnitedHealthcare Member myuhc.com myuhc.com Tracking Your Healthy Rewards on myuhc.
Dear Member, Now that you have enrolled in the Health Reimbursement Medical Plan option, we wanted to provide you with important information about your health reimbursement account (HRA). Accessing Your
More informationTransitioning to Express Scripts
Transitioning to Express Scripts Welcome to Express Scripts. We re pleased to announce that, beginning January 1, 2017 the Michigan Tech prescription benefit will be managed by Express Scripts. Express
More informationTexas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request
Form 1033 September 2017-E Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request About Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious
More informationCombination Products at US FDA
Multimodal Therapies for Brain Disorders: Session II Regulatory and Reimbursement Considerations Combination Products at US FDA Patricia Y. Love, MD, MBA Deputy Director Office of Combination Products,
More informationImportant Prescription Benefit Information
Important Prescription Benefit Information Prepared Exclusively for: Wichita Center for Graduate Medical Education HDHP Plan medtrakrx.com Welcome to MedTrakRx Dear Member: This booklet contains important
More information2017 Small Group Incentive Wellness For Metallic Plans Employer Q & A
2017 Small Group Incentive Wellness For Metallic Plans Employer Q & A 2017 SGIWQA-CC 102016 General Program Information Q. What is the Small Group Incentive Wellness program? A. The Small Group Incentive
More informationMay 26, Re: IVIG Administration Codes, RAC Audits
May 26, 2011 Re: IVIG Administration Codes, RAC Audits Arnold Balanoff, MD Chief Medical Officer Office of the Regional Administrator 601 E. 12th Street, Suite 235 Kansas City, MO 64106 In order to provide
More informationA Review of Canadian EAP Policies Rick Csiernik a a
This article was downloaded by: [Canadian Research Knowledge Network] On: 30 July 2010 Access details: Access Details: [subscription number 783016864] Publisher Routledge Informa Ltd Registered in England
More informationIntroduction PART. 1 Why Technicians Need to Study Pharmacology and Therapeutics. 2 Pharmacokinetics
PART Introduction 1 1 Why Technicians Need to Study Pharmacology and Therapeutics 2 Pharmacokinetics Understanding Pharmacology for Pharmacy Technicians 1 CHAPTER 1 Why Technicians Need to Study Pharmacology
More informationGeneral Introduction
Retention Guidelines for Common Administrative Records of the Government of Canada General Introduction Final Version, December 11, 2006 Table of Contents Overview Introduction Purpose and content of these
More informationAnnual Report 2016/17
Annual Report 2016/17 Compiled by Rob Hollingsworth, Mark Foster MDSAS 1 Database CHAPTER 1 Overview Rob Hollingsworth Introduction As is the case each year, I would firstly like to thank all Trusts and
More informationClinical Policy: Filgrastim, Filgrastim-sndz, Tbo-filgrastim Reference Number: CP.PHAR.297
Clinical Policy: Reference Number: CP.PHAR.297 Effective Date: 12/16 Last Review Date: 10/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationImpact of New Proposals on Name Creation for 87 th PTMG Conference Vienna, Austria
Impact of New Proposals on Name Creation for 87 th PTMG Conference Vienna, Austria Susan M. Proulx, PharmD President, Med-ERRS www.med-errs.com A subsidiary of the Institute for Safe Medication Practices
More informationManagement and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility
Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility Document Detail Document type Standard Operating Procedure CRF-STU-SOP-1: Management and Accountability
More informationFDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives
Session Overview (1) Although the role of the Qualified Person responsible for Pharmacovigilance is mandated by the European legislation, the QPPV is held responsible for the establishment and the maintenance
More informationIHE Patient Care Coordination (PCC) Technical Framework Supplement. Immunization Content (IC) Trial Implementation
Integrating the Healthcare Enterprise 5 IHE Patient Care Coordination (PCC) Technical Framework Supplement 10 Immunization Content (IC) Trial Implementation 15 20 Date: September 9, 2011 Author: IHE PCC
More informationWEST VIRGINIA SCHOOL OF OSTEOPATHIC MEDICINE Office of Human Resources. Stay at Work Program
WEST VIRGINIA SCHOOL OF OSTEOPATHIC MEDICINE Office of Human Resources Stay at Work Program Revised December, 2013 Disclaimer This document should serve as a guideline and should not be construed to supersede
More informationThe views and opinions expressed in the following PowerPoint slides are
Indications, Dosage and Administration, Clinical Studies, Clinical Pharmacology sections of a CCDS Presented by: Mary Jane Boyle Head, Worldwide Product Labeling Merck & Co., 13-October-2011 The views
More informationMeaningful Use Stage 2- Core Measure 01 CPOE Configuration Guide
TouchWorks EHR Meaningful Use Stage 2- Core 01 CPOE Configuration Guide Last Updated: February 10, 2014 Copyright 2013 Allscripts Healthcare, LLC. www.allscripts.com MU Core 01 CPOE This guide will provide
More informationProject Destiny Summary
Project Destiny Summary The American Pharmacists Association (APhA), the National Association of Chain Drug Stores (NACDS), and the National Community Pharmacists Association (NCPA) have joined together
More informationVACCINE AND TB SKIN TEST INFORMATION
VACCINE AND TB SKIN TEST INFORMATION Please click on the appropriate link below to obtain vaccine and TB skin test information for the Health Science programs. Questions? Call the appropriate program director/coordinator
More informationLearn more about why severe RSV disease APPROVED USE
Learn more about why severe RSV disease can turn a welcome home into a welcome back to the hospital APPROVED USE SYNAGIS (palivizumab) is a prescription medication that is used to help prevent a serious
More informationRepublic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a
Republic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a March 15, 1989 ADMINISTRATIVE ORDER No. 67 s. 1989 SUBJECT: Revised Rules and Regulations on Registration of Pharmaceutical
More informationSOA in the pan-canadian EHR
SOA in the pan-canadian EHR Dennis Giokas Chief Technology Officer Solutions Products and Group Canada Health Infoway Inc. 1 Outline Infoway EHR Solution EHRS Blueprint Overview Oriented Architecture Business
More informationEffective Date: April 19, 2018 TITLE: GUIDELINE FOR RADIATION SAFETY COMMITTEE REVIEW OF HUMAN RESEARCH STUDIES. Table of Contents
Version: 2 Page: 1 of 6 Table of Contents 1.0 Introduction... 2 1.1 Purpose... 2 1.2 Scope... 2 1.3 Definitions... 2 2.0 Initial Protocol Review... 2 3.0 Radiation Risk Language... 3 4.0 Non-radiological
More informationImplants for surgery Active implantable medical devices. Part 3: Implantable neurostimulators
Provläsningsexemplar / Preview INTERNATIONAL STANDARD ISO 14708-3 Second edition 2017-04 Implants for surgery Active implantable medical devices Part 3: Implantable neurostimulators Implants chirurgicaux
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS
European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS
More informationCROSS-CANADA DEFINITION OF UNION PRIVATE SECTOR. Statute s Definition of Trade Union Union or Labour Organization
CROSS-CANADA DEFINITION OF UNION PRIVATE SECTOR Jurisdiction Statute Uses Trade Union? Legislation Reference Statute s Definition of Trade Union Union or Labour Organization Canada Yes Trade Union s.3(1)
More informationTESTING COMPLIANCE OF DRUG TAKING-A SIMPLE BED SIDE METHOD
TESTING COMPLIANCE OF DRUG TAKING-A SIMPLE BED SIDE METHOD N. Thilothammal P.V. Krishnamurthy K. Banu S. Gandhimathy ABSTRACT Assessment of compliance in drug taking is a problem in a crowded Outpatient
More informationPAN-CANADIAN PUBLIC HEALTH COMMUNICABLE DISEASE SURVEILLANCE AND MANAGEMENT PROJECT
APPLICATION OVERVIEW PAN-CANADIAN PUBLIC HEALTH COMMUNICABLE DISEASE SURVEILLANCE AND MANAGEMENT PROJECT Copyright Province of British Columbia All rights reserved Disclaimer All reasonable care has been
More informationFDA approval of emergency expanded access use may be requested by telephone, facsimile, or other means of electronic communications.
Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of an Individual Patient with an Investigational Drug or a REMS-restricted, Approved Drug Guidelines:
More informationThe Investigator s Brochure: A multidisciplinary document
The Investigator s Brochure: A multidisciplinary document Douglas Fiebig Trilogy Writing & Consulting GmbH, Frankfurt am Main, Germany Correspondence to: Douglas Fiebig Trilogy Writing & Consulting GmbH,
More information